Copyright © 2016 McGraw-Hill Education. All rights reserved.

Slides:

Advertisements

Similar presentations

Drug treatment for chronic hepatitis B Implementing NICE guidance NICE technology appraisal guidance 96, 153, 154, 173 Updated 2009.

Advertisements

The Hepatitis B&C Past and Present Martin J Spitz MD FACP AGAF Clinical Professor of Medicine UCSF.

Geoffrey DUSHEIKO. Nucleosides for HBeAg-positive chronic hepatitis B G Dusheiko Centre for Hepatology Royal Free and University College School of Medicine.

Professor George KK Lau The University of Hong Kong Hong Kong SAR, China HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated.

BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A.

Anna LOK. Management of Antiviral Resistant Hepatitis B Clinical Case Anna S. F. Lok University of Michigan Ann Arbor, MI, USA.

Case study: Chronic HBV infection Marion Peters University of California San Francisco 2009.

Hepatitis web study H EPATITIS W EB S TUDY Therapeutic Agents Used to Treat Hepatitis B Presentation Prepared by: Nina Kim, MD and David Spach, MD Last.

1 3 rd Paris Hepatitis Congress, 20/1/09 HBeAg-positive patient: Why do I treat with nucleos/tide analogs? Samuel S. Lee University of Calgary Calgary,

TELBIVUDINE FOR THE TREATMENT OF CHRONIC HEPATITIS B: A CASE SERIES N.K. Gatselis, K. Zachou, E.I. Rigopoulou, G. Papadamou, K. Galanis G.N. Dalekos Department.

Slide #1 CL Thio, MD. Presented at RWCA Clinical Update, August Optimizing Hepatitis B Virus Treatment in HIV-Infected Individuals Chloe L. Thio,

Robert PERRILLO. 2 nd Paris Hepatitis Conference Why Do I Treat my HBeAg Negative Chronic Hepatitis B Patients with Pegylated Interferon.

Stephanos HADZIYANNIS. Following HBeAg seroconversion a proportion of patients retains or redevelops significant HBV replication associated with persistent.

3 rd Paris Hepatitis Conference January, 20th 2009 How to optimize the management of my HBeAg negative patients? Pietro Lampertico 1st Gastroenterology.

Rafael ESTEBAN. New Drugs for Chronic Hepatitis B R. Esteban, M.D. Hospital General Universitario Valle de Hebron Barcelona.

CHRONIC HEPATITIS B SEROLOGY. Antigens HBsAg -Found on the surface of the intact virus and in serum as unattached particles -Earliest detectable marker.

Can One Pill A Day Keep Hepatitis B Away? Scott K. Fung, MD, FRCPC Toronto General Hospital University of Toronto November 30, 2009 TGH.

George LAU. Hepatitis B e antigen positive patients: Why do I treat my patient with pegylated interferon? 2nd Hepatitis Paris conference George KK Lau,

1. Sustained suppression of HBV replication Decrease in serum HBV DNA to

Yves BENHAMOU. Management of Patients with HIV/HBV Co-infection Yves Benhamou Hepatology Department Groupe Hospitalier Pitié Salpétrière Paris, France.

Gui-Qiang Wang Department of Infectious Diseases

Management of Resistance: Implications for Treatment Choices

Surrogate Endpoints for Hepatitis B Trials Greg Soon, Ph.D Rafia Bhore, Ph.D. Division of Biometrics III/Antiviral 8/7/2002 AC.

On-treatment management for chronic hepatitis B (CHB) in patients receiving oral antiviral therapy Byung-Ho Kim Kyung Hee University School of Medicine.

Maria Buti, MD Professor of Medicine Hospital Universitario Vall d'Hebron Barcelona, Spain Clinical Focus: Impact of HBV Therapy on Liver Fibrosis and.

Copyright 2007 The ACT-HBV Korea & UMT. All Rights Reserved 강동 경희대병원 소화기내과 이 정일 만성 B 형 간염의 치료.

Jung Min Lee, Sang Hoon Ahn, Hyon Suk Kim, Hana Park, Hye Young Chang, Do Young Kim, Seong Gyu Hwang, Kyu Sung Rim, Chae Yoon Chon, Kwang-Hyub Han, and.

Hepatitis B virus infection in renal transplant recipients

Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:

Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen–Positive Patients with Chronic Hepatitis B : A Randomized International Study of Entecavir.

Publication stage: In Press Accepted Manuscript

Copyright © 2016 McGraw-Hill Education. All rights reserved.

Evidence-based Treatment for Hepatitis B Infection

Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC Treatment Selection for HBV-Infected Patients With Decompensated.

From: Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney DiseaseA Secondary Analysis.

A chamber designed to treat multiple patients

Clinical Focus: Impact of HBV Therapy on Liver Fibrosis and Cirrhosis

Copyright © 2004 American Medical Association. All rights reserved.

Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.

Copyright © 2007 American Medical Association. All rights reserved.

HBV Management in 2012… Where Are We Heading?

Volume 67, Issue 2, Pages (August 2017)

Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience M.-C.

How to optimize the management of my HBeAg negative patients?

Volume 140, Issue 1, Pages (January 2011)

التهاب الكبد الوبائي Viral Hepatitis

Volume 125, Issue 1, Pages (July 2003)

CHRONIC HEPATITIS B Dr.mousavi-Abadan CHRONIC HEPATITIS B Dr.mousavi-Abadan-1397.

Volume 123, Issue 6, Pages (December 2002)

Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective.

Volume 50, Issue 4, Pages (April 2009)

How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? Neil Rajoriya,

Volume 133, Issue 5, Pages (November 2007)

Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency Danny Ka-Ho Wong, Wai-Kay.

American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive.

Volume 139, Issue 4, Pages e3 (October 2010)

Chronic Hepatitis B: Current Testing Strategies

A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China Y. Zhang,

Volume 66, Issue 1, Pages (January 2017)

Volume 126, Issue 1, Pages (January 2004)

A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China

Volume 44, Issue 2, Pages (February 2006)

Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients Eun-Sook Park, Ah Ram Lee, Doo Hyun Kim, Jeong-Hoon.

Treatment of hepatitis B in patients with chronic kidney disease

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong

Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients H.-Y. Pan, H.-Y. Pan,

Reply Gastroenterology

Emmet B. Keeffe, Douglas T

Presentation transcript:

Copyright © 2016 McGraw-Hill Education. All rights reserved. From: Chronic Hepatitis Harrison's Principles of Internal Medicine, 19e, 2015 Legend: Relative potency of antiviral drugs for hepatitis B, as reflected by median log10 HBV DNA reduction in HBeAg-positive chronic hepatitis B. These data are from individual reports of large, randomized controlled registration trials that were the basis for approval of the drugs. In most instances, these data do not represent direct comparisons among the drugs, because study populations were different, baseline patient variables were not always uniform, and the sensitivity and dynamic range of the HBV DNA assays used in the trials varied. ADV, adefovir dipivoxil; ETV, entecavir; LAM, lamivudine; PEG IFN, pegylated interferon α2a; TBV, telbivudine; TDF, tenofovir disoproxil fumarate. Date of download: 9/19/2016 Copyright © 2016 McGraw-Hill Education. All rights reserved.